New York State Teachers Retirement System Grows Stock Holdings in Alkermes plc (NASDAQ:ALKS)

New York State Teachers Retirement System lifted its position in Alkermes plc (NASDAQ:ALKS) by 14.3% during the third quarter, Holdings Channel reports. The institutional investor owned 90,111 shares of the company’s stock after buying an additional 11,289 shares during the quarter. New York State Teachers Retirement System’s holdings in Alkermes were worth $2,522,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. V Square Quantitative Management LLC acquired a new stake in Alkermes in the third quarter valued at approximately $29,000. Signaturefd LLC lifted its holdings in shares of Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after purchasing an additional 480 shares during the last quarter. Hexagon Capital Partners LLC boosted its position in shares of Alkermes by 3,841.0% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after purchasing an additional 1,498 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Alkermes by 44.4% in the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC purchased a new position in Alkermes during the 2nd quarter worth $116,000. Institutional investors own 95.21% of the company’s stock.

Alkermes Trading Down 1.1 %

NASDAQ ALKS opened at $28.97 on Friday. Alkermes plc has a 1 year low of $22.06 and a 1 year high of $32.88. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The company has a market capitalization of $4.69 billion, a PE ratio of 14.86, a P/E/G ratio of 0.89 and a beta of 0.47. The company has a fifty day moving average of $27.65 and a 200 day moving average of $26.03.

Insider Buying and Selling at Alkermes

In other news, EVP Craig C. Hopkinson sold 10,471 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the sale, the executive vice president now owns 99,238 shares in the company, valued at $2,930,498.14. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ALKS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. decreased their price target on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price objective (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and boosted their target price for the stock from $25.00 to $36.00 in a research report on Tuesday. Cantor Fitzgerald decreased their price target on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, Robert W. Baird boosted their price objective on shares of Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.